NYSE · HAE

Haemonetics Corporation

$82.61 +$3.83 (+4.86%) 1D Market open
Session Pulse Regular session 1 mentions on Fri · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$3.58B
Market cap
36.79×
P/E · TTM
$1.33B
Revenue · TTM
$97.31M
Net income
EPS · TTM $1.89
Dividend yield —
Free cash flow $260.44M
Beta · 1Y 0.25
EBITDA · TTM $189.23M
Gross margin 59.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 6
    The stock moved -8.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.58B
Enterprise value$4.56B
Shares outstanding45.4M
52-wk range$47.32 – $87.32
Avg volume · 20D588.7K
Net cash −$979.14M
Book value / share$15.49
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Haemonetics Corporation
IPO dateMay 9, 1991
Employees3009

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E36.79
P/S2.68
P/FCF13.75
EV/EBITDA24.09
EV/Sales3.42
Graham №$25.69

Profitability

Gross 59.0%
Operating 9.6%
Net 7.3%
FCF 19.5%
ROE / ROIC 12.0% · 5.5%

Financial Health

Current ratio2.95
Quick ratio1.87
Debt / equity1.54
Debt / EBITDA 6.47
Net cash −$979.14M
Working capital$552.28M

Cash Flow · TTM

Operating CF $293.22M
Capex −$32.78M
Free cash flow $260.44M
Buybacks $175.00M
Dividends paid —
Shareholder yield 4.9%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

—
Insufficient balance-sheet inputs

Graham Number vs Price

$25.69 vs $79.91
Trades 3.1× above classic defensive value — priced for growth
Fundamentals through 2025-12-27 · computed by TickerWolf from SEC filings